Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Addressing key challenges in adjuvant therapy for renal carcinoma

Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines critical questions in the management of renal carcinoma, particularly regarding adjuvant therapy. He emphasizes the lack of effective biomarkers to identify patients who would benefit most from such treatments, and there is uncertainty about the best course of action for patients progressing on adjuvant therapy. Such strategies are needed to improve the cure rate and quality of life for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.